{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:15:52Z","timestamp":1741324552564,"version":"3.38.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.repc.2024.11.008","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T11:11:21Z","timestamp":1739531481000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Targeted disease-specific therapy for patients with hereditary transthyretin amyloidosis and cardiac involvement after orthotopic liver transplantation. Consensus from the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology and National Reference Centers for Familial Amyloidosis"],"prefix":"10.1016","volume":"44","author":[{"given":"S\u00edlvia","family":"Aguiar Rosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2024.11.008_bib0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.repc.2024.11.008_bib0285","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.repc.2024.11.008_bib0290","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.repc.2024.11.008_bib0295","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.repc.2024.11.008_bib0300","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.repc.2024.11.008_bib0305","doi-asserted-by":"crossref","first-page":"e016614","DOI":"10.1161\/JAHA.120.016614","article-title":"Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence-based recommendations","volume":"9","author":"Marques","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.008_bib0310","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0315","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0320","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0325","doi-asserted-by":"crossref","first-page":"e0143456","DOI":"10.1371\/journal.pone.0143456","article-title":"Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis \u2013 impact of sex and amyloid fibril composition","volume":"10","author":"Arvidsson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2024.11.008_bib0330","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"Koike","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.repc.2024.11.008_bib0335","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.repc.2024.11.008_bib0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis \u2013 report from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2024.11.008_bib0345","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.repc.2024.11.008_bib0350","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","article-title":"Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients","volume":"7","author":"Yazaki","year":"2007","journal-title":"Am J Transpl"},{"key":"10.1016\/j.repc.2024.11.008_bib0355","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00109-010-0695-1","article-title":"Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis","volume":"89","author":"Ihse","year":"2011","journal-title":"J Mol Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/13506129.2018.1550061","article-title":"Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy","volume":"25","author":"Algalarrondo","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.008_bib0365","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0370","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.008_bib0375","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.008_bib0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.repc.2024.11.008_bib0385","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.008_bib0390","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2 \u2013 diagnostic criteria and appropriate utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.008_bib0395","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.008_bib0400","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0405","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis \u2013 understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.008_bib0410","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.008_bib0415","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.008_bib0420","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-023-06459-y","article-title":"Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?","volume":"51","author":"Tingen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.repc.2024.11.008_bib0425","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis\u2013understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.008_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.repc.2024.11.008_bib0435","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.repc.2024.11.008_bib0440","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.repc.2024.11.008_bib0445","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0450","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0455","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0460","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3988\/jcn.2017.13.4.444","article-title":"Tafamidis for a transplant patient with transthyretin amyloid polyneuropathy","volume":"13","author":"Romero-Imbroda","year":"2017","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.repc.2024.11.008_bib0465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0470","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.008_bib0475","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.repc.2024.11.008_bib0480","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.008_bib0485","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0490","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0495","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2024.11.008_bib0500","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.repc.2024.11.008_bib0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.008_bib0510","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","article-title":"TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients","volume":"27","author":"Moshe-Lilie","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.008_bib0515","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","article-title":"Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis","volume":"36","author":"Nuvolone","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.repc.2024.11.008_bib0520","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0525","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0530","first-page":"e202304","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.repc.2024.11.008_bib0535","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.008_bib0540","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.008_bib0545","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","article-title":"J. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.repc.2024.11.008_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231191590","article-title":"A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis","volume":"16","author":"Casasnovas","year":"2023","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255125000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255125000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:30:37Z","timestamp":1741271437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255125000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":55,"alternative-id":["S0870255125000228"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2024.11.008","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted disease-specific therapy for patients with hereditary transthyretin amyloidosis and cardiac involvement after orthotopic liver transplantation. Consensus from the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology and National Reference Centers for Familial Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2024.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}